Sotagliflozin given pre- or shortly post-discharge to patients with type 2 diabetes (T2D) recently hospitalized for worsening heart failure (HF) may result in a reduced risk of cardiovascular (CV) death, hospitalization, or urgent visits for HF, according to results of the phase III SOLOIST-WHF* trial.
A single polypill combining a beta blocker, ACE* inhibitor, statin, and diuretic, in addition to a daily dose of aspirin, significantly reduced the risk of cardiovascular disease (CVD) in patients with intermediate CV risk, according to the TIPS**-3 study presented at the AHA 2020 Scientific Sessions.
Patients with high cardiovascular (CV) risk who received a high-dose trivalent influenza vaccine over three influenza seasons did not have a lower risk of cardiopulmonary hospitalization or death compared with those who received a standard-dose quadrivalent vaccine, according to the INVESTED* trial presented at AHA 2020.
In patients with recurrent pericarditis (RP), the interleukin (IL)-1α and IL-1β cytokine trap rilonacept significantly reduced the risk of recurrence, with rapid resolution of episodes, the RHAPSODY* trial has shown.
Obesity, particularly the severe class, was associated with an increased risk of mechanical ventilation and death in patients hospitalized with COVID-19 — a risk that is even more profound among the younger age group, reveals data from the AHA COVID-19 CVD registry*.
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Intravenous (IV) iron supplementation with ferric carboxymaltose (FCM) reduces the risk of subsequent hospitalization for heart failure (HF) in iron-deficient patients after an episode of acute HF, shows the AFFIRM-AHF trial presented at the AHA 2020 Meeting.
Treatment with finerenone led to significantly reduced risk of cardiovascular (CV) events in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), regardless of their CV disease (CVD) history, according to the FIDELIO-DKD* trial presented at AHA 2020.
Adding ticagrelor to aspirin significantly reduces the risk of stroke and death compared with aspirin alone in patients with plaque build-up in their arteries known as ipsilateral atherosclerotic stenosis — thus highlighting the patient subgroup most likely to benefit from the combination therapy, based on a prespecified analysis of the THALES* study.
Laparoscopic tubal reanastomosis yields better pregnancy outcomes and may be more cost-effective than in-vitro fertilization (IVF) treatment in women who wish to conceive after tubal ligation surgery, according to a Singapore study.
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.
Use of a levonorgestrel intrauterine device (IUD) can help reduce menstrual bleeding in adolescents with disabilities — thus providing an option for menstrual management in this population with special needs, in whom data on IUD use are lacking.